Gastrointestinal tumors: Metastasis and tetraspanins;Malignome des magen-darm-traktes: Metastasierung und tetraspanine

Zeitschrift fur Gastroenterologie

Volumn 44, Issue 7, 2006, Pages 573-586

  Zöller, Margot ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; CD82 KAI1; CO 029; Tetraspanins; Tumor progression

Indexed keywords

CATHEPSIN; CD82 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CHEMOKINE RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; GROWTH FACTOR; HEPARANASE; HERMES ANTIGEN; INTEGRIN; MATRIX METALLOPROTEINASE; PLASMIN; TETRASPANIN; TRYPSIN; UROKINASE;

ANGIOGENESIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STEM CELL; CANCER SURVIVAL; CELL MOTILITY; CELL TRANSFORMATION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; GASTROINTESTINAL TUMOR; HUMAN; METASTASIS; MORPHOGENESIS; PANCREAS CANCER; PHENOTYPE; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATOR GENE; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE CANCER; STOMACH CANCER; SUPPRESSOR GENE; SURVIVAL RATE; THROMBOSIS; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD; GASTROINTESTINAL NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 33746733680     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-926795     Document Type: Review

References (212)

1. Shang J, Pena AS. Multidisciplinary approach to understand the pathogenesis of gastric cancer. World J Gastroenterol 2005; 11: 4131-4139
2. Moehler M, Teufel A, Galle PR. New chemotherapeutic strategies in colorectal cancer. Recent Results Cancer Res 2005; 165: 250-259
3. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108
4. Keleg S, Büchler P, Ludwig R et al. Invasion and metastasis in pancreatic cancer. Mol Cancer 2003; 2: 14
5. Dixon E, Vollmer Jr CM, Sahajpal A et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg 2005; 241: 385-394
6. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001; 411: 375-379
7. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458
8. Auerbach R. Patterns of tumor metastasis: organ selectivity in the spread of cancer cells. Lab Invest 1988; 58: 361-364
9. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest 1994; 70: 6-22
10. Damjanov I, Solter D. Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host. Nature 1974; 249: 569-571
11. Fialkow PJ, Martin PJ, Najfeld V et al. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158-163
12. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56
13. Prindull G, Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 2004; 103: 2892-2899
14. Blau HM, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105: 829-841
15. Quesenberry PJ, Colvin GA, Lambert JF. The chiaroscuro stem cell: a unified stem cell theory. Blood 2002; 100: 4266-4271
16. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003; 15: 740-746
17. Jechlinger M, Grunert S, Beug H. Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling. J Mammary Gland Biol Neoplasia 2002; 7: 415-432
18. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002; 4: 487-494
19. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558
20. Schramek H, Feifel E, Marschitz I et al. Loss of active MEK1-ERK1/2 restores epithelial phenotype and morphogenesis in transdifferentiated MDCK cells. Am J Physiol Cell Physiol 2003; 285: C652-661
21. Janda E, Lehmann K, Killisch I et al. Ras and TGF(beta) cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156: 299-313
22. Yamashita S, Miyagi C, Fukada T et al. Zinc transporter LIVI controls epithelial-mesenchymal transition in zebrafish gastrula organizer. Nature 2004; 429: 298-302
23. Cano A, Perez-Moreno MA, Rodrigo I et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83
24. Prindull G. Hypothesis: cell plasticity, linking embryonal stem cells to adult stem cell reservoirs and metastatic cancer cells? Exp Hematol 2005; 33: 738-746
25. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-1487
26. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002; 3: 155-166
27. Yang J, Mani SA, Donaher JL et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-939
28. Huber MA, Azoitei N, Baumann B et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114: 569-581
29. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161-174
30. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 2003; 4: 657-665
31. Brabletz T, Jung A, Spaderna S et al. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749
32. Linares-Cruz G, Bruzzoni-Giovanelli H, Alvaro V et al. p21WAF-1 reorganizes the nucleus in tumor suppression. Proc Natl Acad Sci USA 1998; 95: 1131-1135
33. Portella G, Cumming SA, Liddell J et al. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 1998; 9: 393-404
34. Rosivatz E, Becker I, Specht K et al. Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002; 161: 1881-1891
35. Nakajima S, Doi R, Toyoda E et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 2004; 10: 4125-4133
36. Holtzer H, Biehl J, Yeoh G et al. Effect of oncogenic virus on muscle differentiation. Proc Natl Acad Sci USA 1975; 72: 4051-4055
37. Tapscott SJ. The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development 2005; 132: 2685-2695
38. de la Serna IL, Ohkawa Y, Berkes CA et al. MyoD targets chromatin remodeling complexes to the myogenin locus prior to forming a stable DNA-bound complex. Mol Cell Biol 2005; 25: 3997-4009
39. Gangenahalli GU, Gupta P, Saluja D et al. Stem cell fate specification: role of master regulatory switch transcription factor PU.1 in differential hematopoiesis. Stem Cells Dev 2005; 14: 40-152
40. Kim L, Kimmel AR. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 2000; 10: 508-514
41. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118: 277-279
42. Mareel MM, Van Roy FM, Bracke ME. How and when do tumor cells metastasize? Crit Rev Oncog 1993; 4: 559-594
43. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998-99
44. Wyckoff JB, Jones JG, Condeelis JS et al. A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 2000; 60:2504-2511
45. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. Breast Cancer Res 2004; 6: 93-101
46. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-442
47. Coussens LM, Tinkle CL, Hanahan D et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-490
48. Tomakidi P, Mirancea N, Fusenig NE et al. Defects of basement membrane and hemidesmosome structure correlate with malignant phenotype and stromal interactions in HaCaT-Ras xenografts. Differentiation 1999; 64: 263-275
49. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000; 6: 324-329
50. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45(Suppl 2): S163-175
51. Menke A, Adler G. TGFbeta-induced fibrogenesis of the pancreas. Int J Gastrointest Cancer 2002; 31: 41-46
52. Berger JC, Vander Griend DJ, Robinson VL et al. Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol Ther 2005; 4(8): Epub ahead of print
53. Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: Raf kinase inhibitor protein. J Cell Biochem 2005; 94: 273-278
54. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 46-54
55. Mercurio AM, Rabinovitz I. Towards a mechanistic understanding of tumor invasion - lessons from the alpha6beta 4 integrin. Semin Cancer Biol 2001; 11: 129-141
56. Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev 2005; 24: 395-402
57. Webb DJ, Parsons JT, Horwitz AF. Adhesion assembly, disassembly and turnover in migrating cells - over and over and over again. Nat Cell Biol 2002; 4: E97-100
58. Dai C, Celestino JC, Okada Y et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001; 15: 1913-1925
59. Brooks PC, Stromblad S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-693
60. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943
61. Lipscomb EA, Mercurio AM. Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression. Cancer Metastasis Rev 2005; 24: 413-423
62. Moos M, Tacke R, Scherer H et al. Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature 1988; 334: 701-703
63. Konstantopoulos K, Hanley WD, Wirtz D. Receptor-ligand binding: "catch" bonds finally caught. Curr Biol 2003; 13: R611-613
64. Witz IP. The involvement of selectins and their ligands in tumor-progression. Immunol Lett 2005; 104: 89-93
65. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res 1997; 71: 241-319
66. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45
67. Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004; 35: 211-231
68. Günthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65: 13-24
69. Günthert U. CD44 in malignant disorders. Curr Top Microbiol Immunol 1996; 213: 271-285
70. Hagedorn HG, Bachmeier BE, Nerlich AG. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas. Int J Oncol 2001; 18: 669-681
71. Skrzydlewska E, Sulkowska M, Koda M et al. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 2005; 11: 1251-1266
72. Werb Z, Vu TH, Rinkenberger JL et al. Matrix-degrading proteases and angiogenesis during development and tumor formation. APMlS 1999; 107: 11-18
73. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001; 13: 534-540
74. Murphy G, Stanton H, Cowell S et al. Mechanisms for pro matrix metalloproteinase activation. APMIS 1999; 107: 38-44
75. Lambert E, Dasse E, Haye B et al. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187-198
76. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22: 205-222
77. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003; 9: 1499-1528
78. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640
79. Myohanen H, Vaheri A. Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 2004; 61: 2840-2858
80. Huovila AP, Turner AJ, Pelto-Huikko M et al. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30: 413-422
81. Ludwig A, Hundhausen C, Lambert MH et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005; 8: 161-171
82. Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32-43
83. Vlodavsky I, Goldshmidt O, Zcharia E et al. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol 2002; 12: 121-129
84. Sanderson RD, Yang Y, Suva LJ et al. Heparan sulfate proteoglycans and heparanase - partners in osteolytic tumor growth and metastasis. Matrix Biol 2004; 23: 341-352
85. Simizu S, Ishida K, Osada H. Heparanase as a molecular target of cancer chemotherapy. Cancer Sci 2004; 95: 553-558
86. Kim JB. Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol 2005; 15: 365-377
87. Presta M, Dell'Era P, Mitola S et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-178
88. Dibrov A, Kashour T, Amara FM. The role of transforming growth factor beta signaling in messenger RNA stability. Growth Factors 2006; 24: 1-11
89. Tanaka T, Bai Z, Srinoulprasert Y et al. Chemokines in tumor progression and metastasis. Cancer Sci 2005; 96: 317-322
90. Zlotnik A. Chemokines in neoplastic progression. Semin Cancer Biol 2004; 14: 181-185
91. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004; 14: 171-179
92. Kucia M, Reca R, Miekus K et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005; 23: 879-894
93. Ding Y, Shimada Y, Maeda M et al. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res 2003; 9: 3406-3412
94. Standal T, Borset M, Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 2004; 26: 179-184
95. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006; 16: 79-87 Epub ahead of print
96. Steeg PS. Perspectives on classic article: metastasis suppressor genes. J Natl Cancer Inst 2004; 96: E4-6
97. Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004; 112: 496-4507
98. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004; 50: 187-196
99. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. Lancet Oncol 2004; 5: 655-663
100. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006; 96: 223-268
101. Maxwell PH. The HIF pathway in cancer. Semin Cell Dev Biol 2005; 16: 523-530
102. Liao F, Li Y, O'Connor W et al. Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 2000; 60: 6805-6810
103. Hashizume H, Baluk P, Morikawa S et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000; 156: 1363-1380
104. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001; 11: 35-40
105. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257
106. Park C, Lugus JJ, Choi K. Stepwise commitment from embryonic stem to hematopoietic and endothelial cells. Curr Top Dev Biol 2005; 66: 1-36
107. Ho HK, Jang JJ, Kaji S et al. Developmental endothelial locus-1 (Del-1), a novel angiogenic protein: its role in ischemia. Circulation 2004; 109: 1314-1319
108. Robinson SC, Coussens LM. Soluble mediators of inflammation during tumor development. Adv Cancer Res 2005; 93: 159-187
109. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410
110. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell 2005; 7: 207-208
111. Murugappan S, Shankar H, Kunapuli SP. Platelet receptors for adenine nucleotides and thromboxane A2. Semin Thromb Hemost 2004; 30: 411-418
112. Boucheix C, Rubinstein E. Tetraspanins. Cell Mol Life Sci 2001; 58: 1189-2205
113. Yunta M, Lazo PA. Tetraspanin proteins as organisers of membrane microdomains and signalling complexes. Cell Signal 2003; 15: 559-564
114. Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 2005; 5: 136-148
115. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005; 6: 801-811
116. Kazarov AR, Yang X, Stipp CS et al. An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. J Cell Biol 2002; 158: 1299-1309
117. Zhu GZ, Miller BJ, Boucheix C et al. Residues SFQ (173-175) in the large extracellular loop of CD9 are required for gamete fusion. Development 2002; 129: 1995-2002
118. Stipp CS, Kolesnikova TV, Hemler ME. Functional domains in tetraspanin proteins. Trends Biochem Sci 2003; 28: 106-112
119. Berditchevski F. Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 2001; 114: 4143-4151
120. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998; 16: 89-109
121. Chattopadhyay N, Wang Z, Ashman LK et al. alpha3beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion. J Cell Biol 2003; 163: 1351-1362
122. Lämmerding J, Kazarov AR, Huang H et al. Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci USA 2003; 100: 7616-7621
123. Herlevsen M, Schmidt DS, Miyazaki K et al. The association of the tetraspanin D6.1A with the alpha6beta4 integrin supports cell motility and liver metastasis formation. J Cell Sci 2003; 116: 4373-4390
124. Yang X, Claas C, Kraeft SK et al. Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol Biol Cell 2002; 13: 767-781
125. Berditchevski F, Odintsova E, Sawada S et al. Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling. J Biol Chem 2002; 277: 36991-37000
126. Clark KL, Oelke A, Johnson ME et al. CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner. J Biol Chem 2004; 279: 19401-19406
127. Claas C, Wahl J, Orlicky DJ et al. The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J 2005; 389: 99-110
128. Cherukuri A, Carter RH, Brooks S et al. B cell signaling is regulated by induced palmitoylation of CD81. J Biol Chem 2004; 279: 31973-31982
129. Claas C, Stipp CS, Hemler ME. Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J Biol Chem 2001; 276: 7974-7984
130. Hakomori SI. Inaugural Article: The glycosynapse. Proc Natl Acad Sci USA 2002; 99: 225-232
131. Kawakami Y, Kawakami K, Steelant WF et al. Tetraspanin CD9 is a "proteolipid," and its interaction with alpha 3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility. J Biol Chem 2002; 277: 34349-34358
132. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 1-39
133. Kovalenko OV, Yang X, Kolesnikova TV et al. Evidence for specific tetraspanin homodimers: inhibition of palmitoylation makes cysteine residues available for cross-linking. Biochem J 2004; 377: 407-417
134. De Curtis I. Cell migration: GAPs between membrane traffic and the cytoskeleton. EMBO Rep 2001; 2: 277-281
135. Hanks SK, Ryzhova L, Shin NY et al. Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility. Front Biosci 2003; 8: 982-996
136. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004; 14: 92-101
137. Zhang XA, Bontrager AL, Hemler ME. Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins. J Biol Chem 2001; 276: 25 005-25 013
138. Shigeta M, Sanzen N, Ozawa M et al. CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J Cell Biol 2003; 163: 165-176
139. Friedl P, Bröcker EB. T cell migration in three-dimensional extracellular matrix: guidance by polarity and sensations. Dev Immunol 2000; 7: 249-266
140. Powelka AM, Sun J, Li J et al. Stimulation-dependent recycling of integrin beta1 regulated by ARF6 and Rab11. Traffic 2004; 5: 20-36
141. Del Pozo MA. Integrin signaling and lipid rafts. Cell Cycle 2004; 3: 725-728
142. Lau LM, Wee JL, Wright MD et al. The tetraspanin superfamily member CD151 regulates outside-in integrin alphaIIbbeta3 signaling and platelet function. Blood 2004; 104: 2368-2375
143. Serru V, Le Naour F, Billard M et al. Selective tetraspan-integrin complexes (CD81/alpha4beta1, CD151/alpha3beta1, CD151/alpha6beta1) under conditions disrupting tetraspan interactions. Biochem J 1999; 340: 103-111
144. Feigelson SW, Grabovsky V, Shamri R et al. The CD81 tetraspanin facilitates instantaneous leukocyte VLA-4 adhesion strengthening to vascular cell adhesion molecule 1 (VCAM-1) under shear flow. J Biol Chem 2003; 278: 51 203-51 212
145. Hung AY, Sheng M. PDZ domains: structural modules for protein complex assembly. J Biol Chem 2002; 277: 5699-5702
146. Murayama Y, Miyagawa J, Oritani K et al. CD9-mediated activation of the p46 Shc isoform leads to apoptosis in cancer cells. J Cell Sci 2004: 117: 3379-3388
147. Tachibana I, Hemler ME. Role of transmembrane 4 superfamily (TM4SF) proteins CD9 and CD81 in muscle cell fusion and myotube maintenance. J Cell Biol 1999; 146: 893-904
148. Ono M, Handa K, Withers DA et al. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res 1999; 59: 2335-2339
149. Delaguillaumie A, Lagaudriere-Gesbert C, Popoff MR et al. Rho GTPases link cytoskeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes. J Cell Sci 2002; 115: 433-443
150. Carloni V, Mazzocca A, Ravichandran KS. Tetraspanin CD81 is linked to ERK/MAPKinase signaling by She in liver tumor cells. Oncogene 2004; 23: 1566-1374
151. Shi W, Fan H, Shum L et al. The tetraspanin CD9 associates with transmembrane TGF-alpha and regulates TGF-alpha-induced EGF receptor activation and cell proliferation. J Cell Biol 2000; 148: 591-602
152. Yan Y, Shirakabe K, Werb Z. The metalloprotease Kuzbanian (ADAM10) mediates the transactivation of EGF receptor by G protein-coupled receptors. J Cell Biol 2002; 158: 221-226
153. Bienstock RJ, Barrett JC. KAI1, a prostate metastasis suppressor: prediction of solvated structure and interactions with binding partners: integrins, cadherins, and cell-surface receptor proteins. Mol Carcinog 2001; 32: 139-153
154. Anzai N, Lee Y, Youn BS et al. C-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors. Blood 2002; 99: 4413-4421
155. Stein KK, Primakoff P, Myles D. Sperm-egg fusion: events at the plasma membrane. J Cell Sci 2004; 117: 6269-6274
156. Schwander M, Leu M, Stumm M et al. Beta1 integrins regulate myoblast fusion and sarcomere assembly. Dev Cell 2003; 4: 673-685
157. Hemler ME. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu Rev Cell Dev Biol 2003; 19: 397-422
158. Garcia E, Pion M, Pelchen-Matthews A et al. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. Traffic 2005; 6: 488-501
159. Kobayashi T, Vischer UM, Rosnoblet C et al. The tetraspanin CD63/lamp3 cycles between endocytic and secretory compartments in human endothelial cells. Mol Biol Cell 2000; 11: 1829-1843
160. Wubbolts R, Leckie RS, Veenhuizen PT et al. Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 2003; 278: 10963-10972
161. Heijnen HF, Van Lier M, Waaijenborg S et al. Concentration of rafts in platelet filopodia correlates with recruitment of c-Src and CD63 to these domains. J Thromb Haemost 2003; 1: 1161-1173
162. Masciopinto F, Giovani C, Campagnoli S et al. Association of hepatitis C virus envelope proteins with exosomes. Eur J Immunol 2004; 34: 2834-2842
163. Denzer K, Kleijmeer MJ, Heijnen HF et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365-3374
164. Butler JS. The yin and yang of the exosome. Trends Cell Biol 2002; 12: 90-96
165. Fevrier B, Raposo G. Exosome secretion: the art of reutilizing nonrecycled proteins? Curr Opin Cell Biol 2004; 16: 415-421
166. de Gassart A, Geminard C, Hoekstra D et al. Exosomes: endosomal-derived vesicles shipping extracellular messages. Traffic 2004; 5: 896-903
167. Zhang XA, Kazarov AR, Yang X et al. Function of the tetraspanin CD151-alpha6beta1 integrin complex during cellular morphogenesis. Mol Biol Cell 2002; 13: 1-11
168. He B, Liu L, Cook GA et al. Tetraspanin CD82 attenuates cellular morphogenesis through down-regulating integrin alpha6-mediated cell adhesion. J Biol Chem 2005; 280: 3346-3354
169. Klein-Soyer C, Azorsa DO, Cazenave JP et al. CD9 participates in endothelial cell migration during in vitro wound repair. Arterioscler Thromb Vasc Biol 2000; 20: 360-369
170. Longo N, Yanez-Mo M, Mittelbrunn M et al. Regulatory role of tetraspanin CD9 in tumor-endothelial cell interaction during transendothelial invasion of melanoma cells. Blood 2001; 98: 3717-3726
171. Wright MD, Geary SM, Fitter S et al. Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 2004; 24: 5978-5988
172. Kagawa H, Nomura S, Miyake T et al. Expression of prothrombinase activity and CD9 antigen on the surface of small vesicles from stimulated human endothelial cells. Thromb Res 1995; 80: 451-460
173. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000; 10: 1009-1012
174. Claas C, Seiter S, Claas A et al. Association between the rat homologue of CO-029, a metastasis-associated tetraspanin molecule and consumption coagulopathy. J Cell Biol 1998; 141: 267-280
175. Testa JE, Brooks PC, Lin JM et al. Eukaryotic expression cloning with an antimetastatic monoclonal antibody identifies a tetraspanin (PETA-3/CD151) as an effector of human tumor cell migration and metastasis. Cancer Res 1999; 59: 3812-3820
176. Wright MD, Moseley GW, van Spriel AB. Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens 2004; 64: 533-542
177. Boucheix C, Duc GH, Jasmin C et al. Tetraspanins and malignancy. Expert Rev Mol Med 2001; Jan 31: 1-17
178. Barrio MM, Bravo AI, Portela P et al. A new epitope on human melanoma-associated antigen CD63/ME491 expressed by both primary and metastatic melanoma. Hybridoma 1998; 17: 355-364
179. Kawashima M, Doh-ura K, Mekada E et al. CD9 expression in solid non-neuroepithelial tumors and infiltrative astrocytic tumors. J Histochem Cytochem 2002; 50: 1195-1203
180. Hori H, Yano S, Koufuji K et al. CD9 expression in gastric cancer and its significance. J Surg Res 2004; 117: 208-215
181. Szala S, Kasai Y, Steplewski Z et al. Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. Proc Natl Acad Sci USA 1990; 87: 6833-6837
182. Hashida H, Takabayashi A, Tokuhara T et al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J Cancer 2003; 89: 158-167
183. Kanetaka K, Sakamoto M, Yamamoto Y et al. Overexpression of tetraspanin CO-029 in hepatocellular carcinoma. J Hepatol 2001; 35: 637-642
184. Sho M, Adachi M, Taki T et al. Transmembrane 4 superfamily as a prognostic factor in pancreatic cancer. Int J Cancer 1998; 79: 509-516
185. Mori M, Mimori K, Shiraishi T et al. Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res 1998; 4: 1507-1510
186. Rinker-Schaeffer CW, Hawkins AL, Ru N et al. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res 1994; 54: 6249-6256
187. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett 2005; Oct28: Epub ahead of print
188. Lombardi DP, Geradts J, Foley JF et al. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 1999; 59: 5724-5731
189. Takaoka A, Hinoda Y, Satoh S et al. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene 1998; 16: 1443-1453
190. Friess H, Guo XZ, Tempia-Caliera AA et al. Differential expression of metastasis-associated genes in papilla of Vater and pancreatic cancer correlates with disease stage. J Clin Oncol 2001; 19: 2422-2432
191. Jackson P, Marreiros A, Russell PJ. KAI1 tetraspanin and metastasis suppressor. Int J Biochem Cell Biol 2005; 37: 530-534
192. Gu J, Tamura M, Pankov R et al. Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol 1999; 146: 389-403
193. Klemke RL, Leng J, Molander R et al. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol 1998; 140: 961-972
194. Kolesnikova TV, Stipp CS, Rao RM et al. EWI-2 modulates lymphocyte integrin alpha4beta1 functions. Blood 2004; 103: 3013-3039
195. Zhang XA, He B, Zhou B et al. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003; 278: 27319-27328
196. Charrin S, Manie S, Thiele C et al. A physical and functional link between cholesterol and tetraspanins. Eur J Immunol 2003; 33: 2479-2489
197. Odintsova E, Voortman J, Gilbert E et al. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J Cell Sci 2003; 116: 4557-4566
198. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006; 25: 2367-2378 Epub ahead of print
199. Lee JH, Park SR, Chay KO et al. KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer. Cancer Res 2004; 64: 4235-4243
200. Bass R, Werner F, Odintsova E et al. Regulation of urokinase receptor proteolytic function by the tetraspanin CD82. J Biol Chem 2005; 280: 14811-14818
201. Geary SM, Cambareri AC, Sincock PM et al. Differential tissue expression of epitopes of the tetraspanin CD151 recognised by monoclonal antibodies. Tissue Antigens 2001; 58: 141-153
202. Tokuhara T, Hasegawa H, Hattori N et al. Clinical significance of CD151 gene expression in non-small cell lung cancer. Clin Cancer Res 2001; 7: 4109-4114
203. Gesierich S, Paret C, Hildebrand D et al. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin Cancer Res 2005; 11: 2840-2852
204. Ang J, Lijovic M, Ashman LK et al. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer Epidemiol Biomarkers Prev 2004; 13: 1717-1721
205. Kohno M, Hasegawa H, Miyake M et al. CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase. Int J Cancer 2002; 97: 336-343
206. Lan R, Liu Z, Song Y et al. Effects of rAAV-CD151 and rAAV-antiCD151 on the migration of human tongue squamous carcinoma cell line Tca8113. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 556-559
207. Shiomi T, Inoki I, Kataoka F et al. Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151. Lab Invest 2005; 85: 1489-1506
208. Sugiura T, Berditchevski F. Function of alpha3beta1-tetraspanin protein complexes in tumor cell invasion. Evidence for the role of the complexes in production of matrix metalloproteinase 2 (MMP-2). J Cell Biol 1999; 146: 1375-1389
209. Sela BA, Steplewski Z, Koprowski H. Colon carcinoma-associated glycoproteins recognized by monoclonal antibodies CO-029 and GA22 - 2. Hybridoma 1989; 8: 481-491
210. Huerta S, Harris DM, Jazirehi A et al. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003; 22: 663-670
211. Bick RL. Platelet function defects: a clinical review. Semin Thromb Hemost 1992; 18: 353-372
212. Kanetaka K, Sakamoto M, Yamamoto Y et al. Possible involvement of tetraspanin CO-029 in hematogenous intrahepatic metastasis of liver cancer cells. Gastroenterol Hepatol 2003; 18: 1309-1314